FT. LAUDERDALE, FL--(MARKET WIRE)--Aug 20, 2008 -- OmniComm Systems, Inc. (OTC BB:OMCM.OB - News), a leader in integrated EDC solutions for clinical trials, today announced that the company is providing EDC software and services for a Phase II trial in BRCA 1/2 and HNPCC patients sponsored by the Tucson Arizona based biotech, Systems Medicine LLC (SML). SML initially began its relationship with OmniComm through OmniComm's CRO Preferred Program(TM) and then selected OmniComm as its EDC vendor of choice for their Phase II study.

"Our initial experience in working with OmniComm was very favorable and as a result we chose to use them in our next trial. We were impressed with their responsiveness and professionalism throughout the entire negotiation and study build process," said Patrick Shannon, Ph.D., Senior Director Project Management for Systems Medicine LLC.

Systems Medicine, LLC (SML) develops oncology products by integrating predictive cellular pharmacogenomics ("genomics") with world-class clinical and regulatory expertise. This allows SML to develop patient-selective therapies by defining the context of vulnerability of cancer and treating only those patients most likely to respond to specific drugs or drug combinations. For more information on SML and the products that SML has in development, please visit www.systems-medicine.com.

"Research organizations are looking at EDC as a strategic imperative to help maximize their investments in today's highly competitive clinical research environment," said Stephen Johnson, COO of OmniComm. "OmniComm is privileged to be partnering with companies like SML that are delivering cutting edge cancer treatments to the marketplace. It gives us great satisfaction to know that our TrialMaster EDC solution helps to speed up that process."

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

     CONTACT:
     Lizanne Kelley
     OmniComm Systems, Inc.
     954-473-1254 Extension 283
     Email Contact